Table 2.
Summary of ATTRACTION-2 and CheckMate-032
| ATTRACTION-2 [1–3] (n = 330) | CheckMate-032 [13] (n = 59) | |
|---|---|---|
| Prior regimens | ||
| 1 | 0 | 10 |
| 2 | 69 | 20 |
| 3 | 137 | 19 |
| >3 | 124 | 10 |
| HER-2 | Not available | |
| Positive | 8 | |
| Negative | 30 | |
| Not available | 21 | |
| PD-L1 ≥1% | ||
| Positive | 16 (MOS 5.22 months) | 16 (DCR 31%) |
| Negative | 114 (MOS 6.05 months) | 26 (DCR 42%) |
| Not available | 200 | 17 |
| MSI high | Not available | |
| Positive | 7 (DCR 71%) | |
| Negative | 18 (DCR 28%) | |
| Not available | 34 | |
| Overall response | (n = 268)* | |
| CR | 3 | 0 |
| PR | 29 | 4 |
| SD | 76 | 18 |
| PD | 124 | 26 |
| Not evaluated | 36 | 6 |
| DCR | 108 (40.3%) | 22 (37%) |
| Median TTR, months | 1.61 (1.4∼3.0) | 1.4 (1.2∼2.1) |
| Median DOR, months | 9.53 (6.14∼9.82) | 14.1 (2.8∼14.1) |
MOS, median overall survival; DCR, disease control rate; TTR, time to response; DOR, duration of response.
*Sixty two excluded from analysis due to no baseline target lesion.